Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder Kresowik TP; Griffith TSImmunotherapy 2009[Mar]; 1 (2): 281-8Mycobacterium bovis bacille Calmette-Guerin (BCG) is one of the great success stories of immunotherapy as a treatment for superficial urothelial carcinoma of the bladder. Despite clinical effectiveness in over 50% of patients, the high incidence of local side effects and presence of nonresponders has led to efforts to improve the therapy. Recent advances have suggested a role for neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in the antitumor inflammatory response. Cell wall components of mycobacteria alone, lowered doses of BCG, and combination with cytokines have been studied as ways to improve the immune response associated with BCG and/or reduce toxicity. This review will discuss the clinical use of BCG, its proposed mechanism of action, and directions of future research to improve efficacy and decrease side effects.|*Immunotherapy[MESH]|Animals[MESH]|Clinical Trials as Topic[MESH]|Cytokines/administration & dosage/adverse effects[MESH]|Humans[MESH]|Mycobacterium bovis/*immunology[MESH]|Neutrophils/immunology/pathology[MESH]|TNF-Related Apoptosis-Inducing Ligand/immunology/*metabolism[MESH]|Urinary Bladder Neoplasms/immunology/pathology/*therapy[MESH]|Urothelium/immunology/pathology[MESH]|Vaccination[MESH] |
